Business Wire

JDE-PEET’S

4.9.2020 08:02:13 CEST | Business Wire | Press release

Share
JDE Peet’s Appoints Fabien Simon as Chief Executive Officer

JDE Peet's (Euronext Amsterdam: JDEP), the world’s largest pure-play coffee and tea group by revenue, today announced the appointment of Fabien Simon as Chief Executive Officer, effective 7 September 2020. He is based in Amsterdam.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200903005811/en/

Simon, who has served as a Director of JDE Peet’s since its listing, has extensive experience within the company and sector. Simon spearheaded the successful listing of JDE Peet’s on the Euronext Amsterdam stock exchange in May 2020, raising €2.58 billion in Europe’s largest IPO of the year. Between August 2014 and January 2019, he was CFO of Jacobs Douwe Egberts (JDE) and led its M&A strategy and multiple large-scale integrations.

“No one knows this business better than Fabien,” said Olivier Goudet, Chairman of JDE Peet’s and CEO & Managing Partner of JAB. “Not only did Fabien lead the successful IPO of JDE Peet’s, he oversaw the very creation of JDE and its transformation into a global coffee & tea powerhouse.”

Simon’s appointment follows the strong performance of JDE Peet’s in the first half of 2020, during which time the company demonstrated the resilience of its business and brands despite the unprecedented economic and social disruption of COVID-19.

“JDE Peet’s is a rare business with a proven track record of performance across economic, market and consumer cycles,” added Simon. “It is a privilege to lead this company into its next phase of growth, building on our unique portfolio of brands, products and channels to meet the needs of our customers and capitalize on the myriad opportunities to gain market share in coffee and tea globally. I look forward to leading this incredible business for years to come.”

Simon succeeds Casey Keller who decided to return to the United States to be with his family who were unable to relocate to Amsterdam due to health and safety implications related to the pandemic.

Goudet added, “On behalf of the Board, I would like to thank Casey for his contributions to this organization. Casey joined Peet’s Coffee as CEO in 2018 and, under his leadership, achieved strong growth and record market share gains. He then took the helm of JDE Peet’s and demonstrated remarkable leadership and great results amidst an extraordinary operating environment. We wish him and his family the very best.”

Simon is appointed as CEO by the Board. The appointment will be tabled for formalization at the next general meeting.

NOTE TO EDITORS – EXECUTIVE BIOGRAPHY & PHOTOGRAPHY

Fabien Simon, a French national who has lived in Amsterdam since 2014, has been a Director of JDE Peet’s since its inception and was responsible for leading its successful listing on the Euronext Amsterdam stock exchange in May 2020. He has also served as Partner and CFO of JAB since January 2019 and as chairman of its pet care platform. Simon will step down from all of his other JAB roles, including his board positions at Keurig Dr Pepper and Krispy Kreme and his JAB CFO role. Between August 2014 and January 2019, Simon was CFO of JDE, during which time he led its M&A strategy and multiple large-scale integrations. Prior to JDE, he spent 13 years at Mars, holding various finance leadership roles, including Asia Pacific CFO, Vice President and CFO Petcare Europe and Finance Director Europe. Simon also spent eight years at Valeo in a variety of leadership roles, including Finance Director. He holds a Master's degree in Finance and Economics from the University of Picardie Jules Verne, Amiens and a Chartered Accountant Certificate. He lives in Amsterdam with his wife and three children.

About JDE Peet’s

JDE Peet’s is the world's largest pure-play coffee and tea group by revenue, serving approximately 130 billion cups of coffee and tea in the financial year ended 31 December 2019 (“FY”) in more than 100 developed and emerging countries. With a portfolio of more than 50 leading global, regional and local coffee and tea brands, JDE Peet’s offers an extensive range of high-quality and innovative coffee and tea products and solutions to serve consumer needs across markets, consumer preferences and price levels. In FY 2019, JDE Peet’s generated total sales of EUR 6.9 billion and had on average 21,255 employees worldwide. The JDE Peet’s global portfolio includes Jacobs, Peet’s, L’OR, Senseo, Tassimo and Ti Ora.

For more information please visit www.JDEPeets.com .

This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye